Pharmaron Beijing Co., Ltd.'s (SZSE:300759) Price Is Right But Growth Is Lacking
Jan 15
Have your own idea? Try our Stock Screener
Chinese (SSE) Clinical Research and Equipment Industry Analysis
UpdatedJan 18, 2025
DataAggregated Company Financials
Companies26
- 7D0.5%
- 3M-4.2%
- 1Y-23.4%
- YTDn/a
In the last week, the Clinical Research and Equipment industry is flat overall, with MGI Tech standing out by going down 4.1%. As for the longer term, the industry has declined 23% in the last year. As for the next few years, earnings are expected to grow by 30% per annum.
Industry Valuation and Performance
Has the Chinese Clinical Research and Equipment Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Sat, 18 Jan 2025 | CN¥352.0b | CN¥88.1b | CN¥11.2b | 37x | 31.3x | 4x |
| Mon, 16 Dec 2024 | CN¥388.6b | CN¥87.8b | CN¥11.2b | 40.1x | 34.7x | 4.4x |
| Wed, 13 Nov 2024 | CN¥411.9b | CN¥87.8b | CN¥11.2b | 44.7x | 36.8x | 4.7x |
| Fri, 11 Oct 2024 | CN¥388.5b | CN¥88.2b | CN¥12.4b | 35.2x | 31.4x | 4.4x |
| Sun, 08 Sep 2024 | CN¥274.1b | CN¥87.1b | CN¥12.3b | 27.9x | 22.3x | 3.1x |
| Tue, 06 Aug 2024 | CN¥299.1b | CN¥87.6b | CN¥12.6b | 28.6x | 23.8x | 3.4x |
| Thu, 04 Jul 2024 | CN¥274.4b | CN¥88.3b | CN¥13.4b | 24.1x | 20.5x | 3.1x |
| Sat, 01 Jun 2024 | CN¥309.0b | CN¥88.3b | CN¥13.4b | 27.5x | 23.1x | 3.5x |
| Mon, 29 Apr 2024 | CN¥318.6b | CN¥90.2b | CN¥14.4b | 30.4x | 22.1x | 3.5x |
| Wed, 27 Mar 2024 | CN¥340.0b | CN¥90.4b | CN¥15.6b | 31.7x | 21.8x | 3.8x |
| Fri, 23 Feb 2024 | CN¥358.3b | CN¥91.1b | CN¥16.1b | 31.8x | 22.3x | 3.9x |
| Sun, 21 Jan 2024 | CN¥452.3b | CN¥91.1b | CN¥16.1b | 35.4x | 28.1x | 5x |
| Tue, 19 Dec 2023 | CN¥475.7b | CN¥91.1b | CN¥16.1b | 37.4x | 29.6x | 5.2x |
| Thu, 16 Nov 2023 | CN¥558.5b | CN¥91.1b | CN¥16.1b | 40.9x | 34.7x | 6.1x |
| Sat, 14 Oct 2023 | CN¥548.6b | CN¥92.0b | CN¥18.3b | 36.2x | 29.9x | 6x |
| Mon, 11 Sep 2023 | CN¥470.0b | CN¥91.9b | CN¥18.3b | 32.3x | 25.7x | 5.1x |
| Wed, 09 Aug 2023 | CN¥480.5b | CN¥91.8b | CN¥18.5b | 34.8x | 26x | 5.2x |
| Fri, 07 Jul 2023 | CN¥452.7b | CN¥91.3b | CN¥18.5b | 34.5x | 24.5x | 5x |
| Sun, 04 Jun 2023 | CN¥499.9b | CN¥91.3b | CN¥18.5b | 38.6x | 27.1x | 5.5x |
| Tue, 02 May 2023 | CN¥514.4b | CN¥92.4b | CN¥19.0b | 43.1x | 27.1x | 5.6x |
| Thu, 30 Mar 2023 | CN¥585.4b | CN¥90.2b | CN¥19.9b | 49.1x | 29.5x | 6.5x |
| Sat, 25 Feb 2023 | CN¥612.5b | CN¥86.6b | CN¥20.8b | 53x | 29.4x | 7.1x |
| Mon, 23 Jan 2023 | CN¥713.5b | CN¥86.6b | CN¥20.8b | 60.6x | 34.3x | 8.2x |
| Wed, 21 Dec 2022 | CN¥554.0b | CN¥86.6b | CN¥20.8b | 46.7x | 26.6x | 6.4x |
| Fri, 18 Nov 2022 | CN¥645.0b | CN¥86.5b | CN¥20.8b | 56.3x | 31x | 7.5x |
| Sun, 16 Oct 2022 | CN¥585.2b | CN¥78.2b | CN¥16.9b | 48.8x | 34.6x | 7.5x |
| Tue, 13 Sep 2022 | CN¥614.4b | CN¥77.8b | CN¥17.0b | 49.6x | 36.1x | 7.9x |
| Thu, 11 Aug 2022 | CN¥623.1b | CN¥73.3b | CN¥17.1b | 67.7x | 36.4x | 8.5x |
| Sat, 09 Jul 2022 | CN¥748.9b | CN¥69.0b | CN¥15.2b | 75.5x | 49.3x | 10.9x |
| Mon, 06 Jun 2022 | CN¥577.0b | CN¥69.0b | CN¥15.2b | 55.6x | 38x | 8.4x |
| Wed, 04 May 2022 | CN¥619.7b | CN¥68.4b | CN¥15.1b | 59x | 41x | 9.1x |
| Fri, 01 Apr 2022 | CN¥679.7b | CN¥62.7b | CN¥15.0b | 68.7x | 45.3x | 10.8x |
| Sun, 27 Feb 2022 | CN¥637.7b | CN¥59.2b | CN¥13.3b | 67.6x | 48.1x | 10.8x |
| Tue, 25 Jan 2022 | CN¥682.5b | CN¥57.5b | CN¥12.3b | 73.2x | 55.4x | 11.9x |
Price to Earnings Ratio
55.4x
Current Industry PE
- Investors are relatively neutral on the Chinese Life Sciences Tools and Services industry at the moment, indicating that they anticipate long term growth rates to remain steady.
- The industry is trading close to its 3-year average PE ratio of 30.9x.
- The 3-year average PS ratio of 6.1x is higher than the industry's current PS ratio of 4.0x.
Past Earnings Growth
- The earnings for companies in the Life Sciences Tools and Services industry have declined 3.0% per year over the last three years.
- Meanwhile revenues for these companies have grown 15% per year.
- This means that although more sales are being generated, either the cost of doing business or the level of investment back into businesses has increased, which has decreased profits.
Industry Comparison
How does Chinese Clinical Research and Equipment compare with similar industries?
| CN Market | 3.49% | |
| Healthcare | 2.59% | |
| Life Sciences | 0.50% | |
| Clinical Research and Equipment | 0.50% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| 300759 Pharmaron Beijing | CN¥25.06 | 3.7% +CN¥1.6b | -2.0% | PE23.5x | |
| 300347 Hangzhou Tigermed Consulting | CN¥49.76 | 1.4% +CN¥594.3m | 1.8% | PE44.7x | |
| 688131 Shanghai Haoyuan Chemexpress | CN¥36.80 | 8.2% +CN¥588.5m | 21.7% | PE50.9x | |
| 603108 Shanghai Runda Medical Technology | CN¥15.00 | 5.0% +CN¥431.2m | -14.3% | PE223.1x | |
| 603127 Joinn Laboratories(China)Co.Ltd | CN¥15.77 | 3.1% +CN¥352.6m | -23.1% | PS5.5x |
